|
|
 |
|
Viewing report
|
|
|
|
Drugs of Tomorrow 2001: Lung Cancer
Datamonitor, Jan 2002
Lung Cancer is currently served by cytotoxic agents, however, survival rates have not improved over the last decade. With a high level of unmet need, innovative products are expected to achieve high clinical uptake. In particular, AstraZeneca''s Iressa will make considerable impact in the lung cancer market in the next five years. Datamonitor''s ‘Drugs of Tomorrow 2002: Lung Cancer -Iressa Driving The Pipeline Market’ provides in-depth analysis of the key pipeline drugs for lung cancer in the seven major pharmaceutical markets including: US, Japan, UK, France, Germany, Spain, Italy. You gain access to: • Accurate and up-to-date R&D information on the focus and direction of the major players in the lung cancer market • Identification of the unmet needs in lung cancer, in drug classes and product pipelines • In-depth comparative analysis of levels of unmet need, R&D focus, drug class and pipeline products for lung cancer • Forecasts of the market potential for each individual drug profiled and predicted for launch between 2002 and 2008
Customers who bought this item also bought
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Drug Pipeline Report
Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Therapy Area Pipeline Report
Pipeline Insight: Non-Small Cell Lung Cancer - Pipeline Set To Offer Only Modest Improvements
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old Regimens
Cancer Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer
Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus Lung Cancer and Melanoma
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma - Limited R&D Activity Provides Opportunity for Early-Phase Pipeline Drugs
Treatment Algorithms 2001: Lung Cancer
Cancer Drug Discoveries: What the Future Holds: Non-Small Cell Lung Cancer Chapter
Cancer Therapeutics - Market Insight and R&D Pipeline Analysis
Chinese Markets for Lung Cancer Treatment Drugs
|
|
|
|
